Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation

Objective A retrospective single-centre study to compare the clinical features of patients with lung adenocarcinoma with and without epidermal growth factor receptor (EGFR) mutations. Methods Pretreatment medical records of patients with lung adenocarcinoma were reviewed. DNA was extracted from paraffin wax-embedded tumour tissue for analysis of EGFR mutations. Malignant pleural effusion (MPE) was diagnosed by cytopathological testing of pleural fluid. Results EGFR mutations (19-Del and L858R) were recorded in 81/283 patients (28.6%). MPE was found in 42/283 patients (14.8%). In patients with stage IV disease, the frequency of EGFR mutations was higher in those with MPE than in those without MPE. EGFR mutations were independently associated with female sex, no history of smoking and presence of MPE. Conclusions There was a positive association between EGFR mutation and the presence of MPE. EGFR mutations may play an important role in the formation of MPE.

• Publication year

  2014

• Venue

  Journal of International Medical Research

• Publication date

  2014-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0300060514539273PMID 25239875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).

  2014cited by this paper
• Epidermal growth factor receptor inhibition in lung cancer: status 2012.

  2013cited by this paper
• Pleural Effusion in Lung Cancer: More Questions than Answers

  2012cited by this paper
• Survival of lung adenocarcinoma patients with malignant pleural effusion

  2012cited by this paper
• EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

  2012cited by this paper
• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

  2012influential reference
• Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer

  2012cited by this paper
• EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma

  2012cited by this paper
• [A simple view on lung cancer biology: The EGFR pathway].

  2011cited by this paper
• Personalized medicine in lung cancer: what we need to know

  2011cited by this paper
• [A simple view on lung cancer biology: the MET pathway].

  2011cited by this paper
• EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.

  2011cited by this paper
• Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

  2011cited by this paper
• Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Genetic and epigenetic changes in lung carcinoma and their clinical implications

  2011cited by this paper
• Lung cancer: epidemiology, etiology, and prevention.

  2011cited by this paper
• A Meta-Analysis

  2009cited by this paper
• The revised TNM staging system for lung cancer.

  2009influential reference
• A small step towards personalized medicine for non-small cell lung cancer.

  2009influential reference
• Prognostic significance of pleural lavage cytology in patients with lung cancer: a meta-analysis.

  2008cited by this paper
• Recent advances in the diagnosis and management of malignant pleural effusions.

  2008cited by this paper
• Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

  2008cited by this paper
• Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma

  2008cited by this paper
• Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.

  2007cited by this paper
• Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

  2005cited by this paper
• CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

  2004cited by this paper
• Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.

  1996cited by this paper
• Management of malignant pleural effusions.

  1993cited by this paper
• The pathophysiology of pleural effusions.

  1990cited by this paper

• Integrating pleural PD-1+CD8+ T cell as a complement variable into LENT score to assess patients with lung adenocarcinoma complicated with MPE.

  2026cites this paper
• Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study.

  2025cites this paper
• Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance

  2025cites this paper
• Prognostic impact of pleural lavage cytology in EGFR-stratified resected non-small cell lung cancer.

  2025cites this paper
• Prevalence of epidermal growth factor receptor (EGFR) mutations and correlation with histological patterns in lung adenocarcinoma in patients from Bosnia and Herzegovina.

  2024cites this paper
• Analysis of tumor abnormal protein expression and epidermal growth factor receptor mutation status in non-small cell lung cancer

  2024cites this paper
• EGFR mutations in patients with lung adenocarcinoma and malignant pleural effusion: a propensity score-matched analysis of a single-center database

  2024cites this paper
• Lymph nodes rather than pleural metabolic activity in 18F-FDG PET/CT correlates with malignant pleural effusion recurrence in advanced non-small cell lung cancer

  2024cites this paper
• Clinical and Molecular Features of Malignant Pleural Effusion in Non-Small Cell Lung Cancer (NSCLC) of a Caucasian Population

  2024cites this paper
• Efficacy of osimertinib in patients with EGFR ‐mutation positive non‐small cell lung cancer with malignant pleural effusion

  2024cites this paper
• The significance and factors leading to heteroploidy in pleural lavage cytology

  2023cites this paper
• Risk factors for refractory malignant pleural effusion and the impact on prognosis in non-small cell lung cancer patients with advanced EGFR mutations: a retrospective cohort study using propensity score matching

  2023cites this paper
• Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion

  2022cites this paper
• Exploring the ‘Dormancy Activation Switch’ in the Tumour Microenvironment for Metastatic Lung Cancer: The Possible Role of MicroRNA

  2021cites this paper
• Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.

  2020cites this paper
• Role of early definitive management for newly diagnosed malignant pleural effusion related to lung cancer

  2020cites this paper
• Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients

  2020cites this paper
• Pleural invasion, epidermal growth factor receptor mutation and carcinoembryonic antigen level affect pleural lavage cytology-positive status in non-small-cell lung cancer.

  2020cites this paper
• Targeted deep sequencing from multiple sources demonstrates increased NOTCH1 alterations in lung cancer patient plasma

  2019cites this paper
• EGFR mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients

  2019cites this paper
• Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer

  2019cites this paper
• Malignant Pleural Effusion from Lung Cancers with Driver Mutations

  2018cites this paper
• Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M

  2018cites this paper
• An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore

  2018cites this paper
• Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases.

  2018cites this paper
• Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis

  2017cites this paper
• Abstract. Lung adenocarcinoma, characterized by its early and aggressive local invasion and high metastatic potential, is the most frequently observed histological type of non-small-cell lung cancer (NSCLC). Visceral pleural invasion (VPI) caused by peripheral lung adenocarcinomas is closely associa

  2017cites this paper
• Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma.

  2017cites this paper
• Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy

  2017cites this paper
• Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura.

  2017cites this paper
• PREVALENCE OF PLEURAL EFFUSIONS IN LUNG CANCER

  2016cites this paper
• Malignant pleural effusions because of lung cancer

  2016cites this paper
• ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma

  2016cites this paper
• Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies.

  2016cites this paper
• 非小细胞肺癌EGFR-TKI治疗临床获益后颅内转移机制研究进展

  2015cites this paper
• Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKI

  2015cites this paper
• Adequacy of Malignant Pleural Effusion for Epidermal Growth Factor Receptor Mutation Analysis Using the Pyrosequencing Method

  2015cites this paper
• Pleural involvement in lung cancer.

  2015cites this paper
• Switching off malignant pleural effusion formation-fantasy or future?

  2015cites this paper
• EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway

  2015cites this paper